Janux Therapeutics (NASDAQ:JANX) Given “Outperform” Rating at William Blair

William Blair reissued their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research note published on Thursday,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

A number of other equities analysts have also issued reports on JANX. Stifel Nicolaus assumed coverage on Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 target price on the stock. Scotiabank cut their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research report on Thursday, November 7th. Finally, UBS Group initiated coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.44.

Janux Therapeutics Trading Down 4.6 %

Shares of JANX stock opened at $48.76 on Thursday. The firm has a fifty day simple moving average of $49.76 and a 200-day simple moving average of $46.30. The company has a market capitalization of $2.56 billion, a PE ratio of -41.67 and a beta of 3.52. Janux Therapeutics has a twelve month low of $7.79 and a twelve month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The business’s revenue was down 82.6% compared to the same quarter last year. Equities research analysts predict that Janux Therapeutics will post -1.34 EPS for the current year.

Insider Activity

In other news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06. Following the completion of the transaction, the insider now owns 7,000 shares in the company, valued at approximately $296,310. This represents a 23.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the sale, the chief executive officer now owns 282,054 shares in the company, valued at approximately $15,101,171.16. This represents a 8.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 420,610 shares of company stock valued at $19,288,666. 29.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently made changes to their positions in the company. Summit Securities Group LLC bought a new position in Janux Therapeutics in the 2nd quarter worth approximately $29,000. Amalgamated Bank boosted its position in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the period. Plato Investment Management Ltd bought a new position in shares of Janux Therapeutics in the second quarter worth $42,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Janux Therapeutics during the second quarter valued at about $151,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.